# Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

> **NCT05764395** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Refractory Melanoma
- Unresectable Melanoma

## Interventions

- **DRUG:** Rigosertib
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT05764395
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-09
- **Primary completion:** 2028-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764395, "Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05764395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*